1. Home
  2. Analysis
  3. Mycophenolate-mofetil
  4. Neoplasm-recurrence

Mycophenolate mofetil and Neoplasm recurrence - a phase IV clinical study of FDA data

Summary:

Neoplasm recurrence is reported as a side effect among people who take Mycophenolate mofetil (mycophenolate mofetil), especially for people who are female, 60+ old, have been taking the drug for 10+ years also take Tacrolimus, and have Immunodeficiency disorders.

The phase IV clinical study analyzes which people have Neoplasm recurrence when taking Mycophenolate mofetil. It is created by eHealthMe based on reports of 93,176 people who have side effects when taking Mycophenolate mofetil from the FDA, and is updated regularly.

What is Mycophenolate mofetil?

Mycophenolate mofetil has active ingredients of mycophenolate mofetil. It is often used in myasthenia gravis. eHealthMe is studying from 93,461 Mycophenolate mofetil users. Check the latest studies of Mycophenolate mofetil.

What is Neoplasm recurrence?

Neoplasm recurrence (reoccurrence of tumour) is found to be associated with 358 drugs and 495 conditions by eHealthMe. Check the latest studies of Neoplasm recurrence.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

93,176 people reported to have side effects when taking Mycophenolate mofetil.
Among them, 33 people (0.04%) have Neoplasm recurrence.

Could Mycophenolate mofetil cause Neoplasm recurrence?

Among these 33 people:

How long have people been on Mycophenolate mofetil when they have Neoplasm recurrence? *

  • < 1 month: 0.0 %
  • 1 - 6 months: 12.5 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 87.5 %

What is the gender of people who have Neoplasm recurrence when taking Mycophenolate mofetil? *

  • female: 65 %
  • male: 35 %

What is the age of people who have Neoplasm recurrence when taking Mycophenolate mofetil? *

  • 0-1: 0.0 %
  • 2-9: 5 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 15 %
  • 40-49: 10 %
  • 50-59: 10 %
  • 60+: 60 %

What are other drugs people take besides Mycophenolate mofetil? *

  1. Tacrolimus: 15 people, 45.45%
  2. Methylprednisolone: 13 people, 39.39%
  3. Prednisolone: 3 people, 9.09%
  4. Cyclosporine: 3 people, 9.09%
  5. Lamivudine: 2 people, 6.06%
  6. Gemcitabine: 2 people, 6.06%
  7. Prednisone: 1 person, 3.03%
  8. Pemetrexed: 1 person, 3.03%
  9. Mylotarg: 1 person, 3.03%
  10. Methotrexate Sodium: 1 person, 3.03%

What are other side effects people have besides Neoplasm recurrence? *

  1. Squamous Cell Carcinoma Of Skin (a cancer of a kind of epithelial cell, the squamous cell. these cells are the main part of the epidermis of the skin): 11 people, 33.33%
  2. Metastases To Bone (cancer spreads to bone): 11 people, 33.33%
  3. Metastases To Lung (cancer spreads to lung): 11 people, 33.33%
  4. Metastases To Lymph Nodes (cancer spreads to lymph node): 10 people, 30.30%
  5. Metastases To Spine (cancer spreads to spine): 10 people, 30.30%
  6. Metastases To Pleura (cancer spreads to pleura): 10 people, 30.30%
  7. Sepsis (a severe blood infection that can lead to organ failure and death): 6 people, 18.18%
  8. Infection: 4 people, 12.12%
  9. Drug Ineffective: 3 people, 9.09%
  10. Disease Progression: 3 people, 9.09%

What are the existing conditions these people have? *

  1. Immunodeficiency Disorders: 5 people, 15.15%
  2. Tuberculosis (a bacterial infection by mycobacterium tuberculosis): 1 person, 3.03%
  3. Systemic Sclerosis (Scleroderma) (an autoimmune or connective tissue disease. it is characterized by thickening of the skin): 1 person, 3.03%
  4. Metastatic Squamous Cell Carcinoma (cancer of squamous cells spreads to other part): 1 person, 3.03%
  5. Chronic Graft Versus Host Disease (immune cells attack the host's body cells after transplant): 1 person, 3.03%
  6. Cholangiocarcinoma (a cancer that forms glands or secretes significant amounts of mucins): 1 person, 3.03%
  7. Bronchopulmonary Aspergillosis (lung disorder caused by aspergillus fungi): 1 person, 3.03%
  8. Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 1 person, 3.03%
  9. Acute Lymphocytic Leukaemia Recurrent (cancer in which the bone marrow makes too many lymphocytes-recurrent): 1 person, 3.03%

* Approximation only. Some reports may have incomplete information.

Do you take Mycophenolate mofetil and have Neoplasm recurrence?

- Check whether Neoplasm recurrence is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Mycophenolate mofetil:

Neoplasm recurrence treatments and more:

How severe was Neoplasm recurrence and when was it recovered:

Expand to all the drugs that have ingredients of mycophenolate mofetil:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Mycophenolate mofetil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neoplasm recurrence:

Browse all the conditions that are associated with Neoplasm recurrence:

How the study uses the data?

The study uses data from the FDA. It is based on mycophenolate mofetil (the active ingredients of Mycophenolate mofetil) and Mycophenolate mofetil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.